In latest setback for stem cell sector, Celyad fails PhIII— and the biotech claims a victory
At first glance, the idea that stem cells can be used to strengthen a damaged heart has a potent attraction. It sounds sensible enough in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
